130 related articles for article (PubMed ID: 1617708)
1. Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.
Gulba DC; Bode C; Sen S; Topp J; Fischer K; Wolf H; Hecker H
Cathet Cardiovasc Diagn; 1992 Jul; 26(3):177-84. PubMed ID: 1617708
[TBL] [Abstract][Full Text] [Related]
2. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
[TBL] [Abstract][Full Text] [Related]
3. Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction.
Gulba DC; Fischer K; Barthels M; Polensky U; Reil GH; Daniel WG; Welzel D; Lichtlen PR
Am J Cardiol; 1989 May; 63(15):1025-31. PubMed ID: 2495709
[TBL] [Abstract][Full Text] [Related]
4. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
5. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
6. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
[TBL] [Abstract][Full Text] [Related]
7. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA
J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of intravenous thrombolytic therapy with pro-urokinase in acute myocardial infarction.
Bode C; Schuler G; Schwarz F; Zimmermann R; Horn A; Kuebler W
Am J Cardiol; 1987 Aug; 60(4):371. PubMed ID: 3113225
[No Abstract] [Full Text] [Related]
9. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
[TBL] [Abstract][Full Text] [Related]
10. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949
[TBL] [Abstract][Full Text] [Related]
11. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
Gulba DC; Barthels M; Westhoff-Bleck M; Jost S; Rafflenbeul W; Daniel WG; Hecker H; Lichtlen PR
Circulation; 1991 Mar; 83(3):937-44. PubMed ID: 1900225
[TBL] [Abstract][Full Text] [Related]
12. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
[TBL] [Abstract][Full Text] [Related]
13. Clot-selective coronary thrombolysis with pro-urokinase.
Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
[TBL] [Abstract][Full Text] [Related]
14. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
[TBL] [Abstract][Full Text] [Related]
15. [A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study].
Kambara H; Kawai C; Kajiwara N; Kammatsuse K; Nitani H; Sasayama S; Kodama K; Sato H; Nobuyoshi M; Nakashima M
Kokyu To Junkan; 1989 Jul; 37(7):749-56. PubMed ID: 2678331
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Kambara H; Kawai C; Kajiwara N; Niitani H; Sasayama S; Kanmatsuse K; Kodama K; Sato H; Nobuyoshi M; Nakashima M
Circulation; 1988 Oct; 78(4):899-905. PubMed ID: 3139325
[TBL] [Abstract][Full Text] [Related]
17. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
[TBL] [Abstract][Full Text] [Related]
18. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
[TBL] [Abstract][Full Text] [Related]
19. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
[TBL] [Abstract][Full Text] [Related]
20. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
